"Novartis" means "commitment to China" in Chinese, that is, to improve the health and quality of life of people in China through innovative products and services. Beijing Novartis Pharmaceutical Co., Ltd. was established in 1987, headquartered in Beijing, and affiliated to Novartis Switzerland.
Novartis is committed to providing innovative health care solutions for patients and society to meet their changing health needs. 20 1 1, the group achieved a net sales of USD 58.6 billion from continuing operations. The Group's investment in R&D is about USD 9.6 billion (USD 9.2 billion after depreciation and amortization). Headquartered in Basel, Switzerland, Novartis Group has business in more than 40 countries and regions around the world, with124,000 full-time employees. Based on its long-term development in China, Novartis Group's important strategic investments include a comprehensive biomedical R&D center in Shanghai, a pharmaceutical factory in Changping, Beijing, and an API factory in Changshu, Jiangsu. For more information, please visit the company website.
Legal Representative: Filippo Jacques Louis Barros.
Date of establishment: 1987-04- 16
Registered capital: USD 30 million.
Area: Beijing.
Unified social credit code: 91100006001684x1.
Business status: Opening.
Industry: manufacturing industry
Company type: limited liability company (wholly owned by foreign legal person)
Staff size: 500-999 people.
Enterprise address: No.31Yong 'an Road, Changping District, Beijing.
Business scope: production of tablets, capsules and gels (latex) (including new compound drugs, new anticancer drugs, new cardiovascular and cerebrovascular drugs, new nervous system drugs and endocrine system drugs, digestive system drugs, anti-infective drugs, antipyretic and analgesic drugs, and new products adopting new technologies of slow release, controlled release, targeting and transdermal absorption); Sub-packaging of imported drugs (soft capsules) (the drug production license is valid until June 5438+February 65438+April 2020); Wholesale drugs; Promotion, consultation and service of Novartis products in China market; Technology import and export; Enterprise management consulting (excluding intermediary services). (Items that need to be examined and approved by the pharmaceutical wholesale according to law shall be subject to business activities in accordance with the approved contents after being approved by the relevant departments. )